Use of PET-CT in the Management of Crohn's Disease

Terminated

• Conditions: Crohn's Disease
• Interventions: Radiation: PET-CT scan

• Registration Number: NCT01182467
• Lead Sponsor: Columbia University

Brief Summary

Crohn's disease (CD) is an autoimmune disorder which affects over 700,000 people in the U.S. The disease can vary in severity and multiple drug classes are available to the disease depending on disease severity and complications. Our purpose will be to study how PET-CT scans can be used to better manage Crohn's Disease.

Detailed Description

Crohn's disease (CD) is a gastrointestinal autoimmune disease thought to result from exposure to luminal antigen. This exposure then results in a robust Th1 mediated immune response which is not downregulated, resulting in intestinal tissue injury. Crohn's disease most commonly involves the distal small intestine, a site that can be difficult to visualize given its central location within the gastrointestinal tract.

A substantial proportion of patients do not respond to any of the standard therapies. Over 40% of patients do not respond to an initial anti-TNF (biologic) agent and approximately 10% per year lose their response to these drugs. There is no standard definition of what constitutes a patient who has primary biologic failure.

Disease activity is measured by indices such as the Crohn's Disease Activity Index (CDAI). The CDAI includes a combination of clinical criteria and lab values. However, the CDAI is limited by reliance on subjective criteria, limiting the score's use as a valid measure of studying response to medical therapy. Clinically, reliance on CDAI can result in inappropriate continuation of an ineffective therapy resulting in worsening of underlying disease, and increasing risk of adverse reactions.

Small studies have demonstrated that PET scans may accurately quantify disease activity in Crohn's. We propose to study CD patients with active flares to assess for a correlation between PET activity and CDAI. Additionally, we will determine whether PET signal intensity is predictive of clinical response to therapy with biologic agents.

The study proposes to test the hypothesis that PET can be used to determine which CD patients with small bowel disease will be true responders (or nonresponders) to biologic therapy at week 12. The use of PET to determine response to biologic therapy in small bowel Crohn's disease would be novel.

Study Timeline

• Study First Submitted: 2010-08-12
• Study First Submitted QC: 2010-08-12
• Study First Posted: 2010-08-16
• Study Start: 2011-02
• Primary Completion: 2013-09
• Study Completion: 2013-09
• Status Verified: 2015-04
• Last Update Submitted: 2015-04-09
• Last Update Posted: 2015-04-10

Recruitment & Eligibility

• Status: TERMINATED
• Sex: All
• Target Recruitment: 5

Inclusion Criteria

• Diagnosis of Crohn's disease
• CDAI1>220
• Identification of small bowel disease based on an imaging study (CT scan, Abdominal ultrasound, MRI), colonoscopy, or histopathology 4. Need for initiation of biologic therapy to control disease process.

Read More

Exclusion Criteria

• Abdominal surgery within 8 wks of study entry
• Change in dose of steroids or immunomodulators within 2wks of study entry
• Pregnancy
• Active bacterial infection or undrained abscess
• Any contraindications to initiation of AntiTNF therapy (i.e. latent tuberculosis).

Read More

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Arm && Interventions

Group	Intervention	Description
Crohn's disease	PET-CT scan	Patients will receieve Radiation: PET-CT scan

Primary Outcome Measures

Name	Time	Method
Pravelence of PET activity with high CDAI score.	Baseline	To determine whether baseline PET SUV-max correlates with response to biologic therapy, as measure by CDAI.

Trial Locations

Locations (1)

Columbia University Medical Center; 🇺🇸 New York, New York, United States